DMAC:DiaMedica Therapeutics Inc Snapshot | Charting | News | Options
$2.53   0.00%  $0.00 NASDAQ 4:08p ET
April 17 '24 		DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of... BusinessWire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
     BusinessWire

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.

    Full Story →

    Headline News
    DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
    4:15p ET March 19 '24 BusinessWire
    DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
    4:13p ET January 29 '24 BusinessWire
    More News →
    Day  0.00%Week  5.86%Month  4.53%More Charting →
    April 25 '24. Markets Closed.
    Last $2.53
    Day change   0.00%$0.00
    Open $NA
    Gap at open $NA
    Previous close $2.53
    Trading volume NA
    10 Day avg vol. 22,362
    Shares out. 38.0Mil
    Market cap. $96.0Mil
    Trading activity Below Avg.
    Previous data from yesterday, April 25 '24.

    Historical Price Performance
    3 month   5.24% 
    6 month   17.67% 
    1 year   59.12% 
    2 year   10.96% 

    Earnings
    Previous 12m -$0.62
    Next 12m Estimate -$0.71
    P/E ratio 4.1x
    Revenue 0Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2024 All rights reserved.